A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521590-13-00

Enrollment

128

Registered

2026-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderately to Severely Active Crohn’s Disease

Brief summary

Deep remission at Week 52

Interventions

DRUGSkyrizi 600 mg concentrate for solution for infusion

DRUGGuselkumab

DRUGSkyrizi 360 mg solution for injection in cartridge

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Deep remission at Week 52	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 29, 2026